4A5 Stock Overview
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Fagron NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €17.42 |
52 Week High | €18.22 |
52 Week Low | €14.73 |
Beta | 0.28 |
1 Month Change | 0.69% |
3 Month Change | 3.38% |
1 Year Change | 3.69% |
3 Year Change | -4.65% |
5 Year Change | 2.23% |
Change since IPO | 74.55% |
Recent News & Updates
Recent updates
Shareholder Returns
4A5 | DE Healthcare | DE Market | |
---|---|---|---|
7D | -0.3% | 2.7% | 0.5% |
1Y | 3.7% | -1.8% | 1.3% |
Return vs Industry: 4A5 exceeded the German Healthcare industry which returned -1.8% over the past year.
Return vs Market: 4A5 exceeded the German Market which returned 1.3% over the past year.
Price Volatility
4A5 volatility | |
---|---|
4A5 Average Weekly Movement | 3.4% |
Healthcare Industry Average Movement | 6.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4A5 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4A5's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 3,282 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron NV Fundamentals Summary
4A5 fundamental statistics | |
---|---|
Market cap | €1.29b |
Earnings (TTM) | €70.55m |
Revenue (TTM) | €762.99m |
18.3x
P/E Ratio1.7x
P/S RatioIs 4A5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4A5 income statement (TTM) | |
---|---|
Revenue | €762.99m |
Cost of Revenue | €430.38m |
Gross Profit | €332.61m |
Other Expenses | €262.07m |
Earnings | €70.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 0.97 |
Gross Margin | 43.59% |
Net Profit Margin | 9.25% |
Debt/Equity Ratio | 69.7% |
How did 4A5 perform over the long term?
See historical performance and comparison